- What is it?
- How does it work?
- How to take and dosage
- Side effects
- Serious infections
- Cancerous growths
- Blood clots
- Drug interactions
Xeljanz is a prescription medication that helps treat moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Xeljanz can reduce swelling and pain in the joints. However, it also weakens the immune system, which can leave people susceptible to infections.
Continue reading this article to learn more about Xeljanz, including when doctors prescribe it, the dosage, side effects, warnings, and interactions with other medications that can occur.
What is it?
In 2012, The Food and Drug Administration (FDA) approved tofacitinib, which is the active ingredient in Xeljanz, to treat moderate to severe rheumatoid arthritis (RA) in people who cannot tolerate methotrexate.
The FDA have also approved Xeljanz to treat moderate to severe ulcerative colitis.
How does it work?
A doctor may prescribe Xeljanz for RA, psoriatic arthritis, and ulcerative colitis.
Xeljanz acts as a Janus kinase (JAK) inhibitor. It prevents inflammatory enzymes called cytokine from stimulating the body’s immune response.
Cytokines include various substances, such as tumor necrosis factor (TNF), interleukins, and transforming growth factor (TGF), that play critical roles in RA and other immune-mediated inflammatory diseases.
When a cytokine binds to a JAK receptor, it begins a chain of chemical reactions that cause systemic, or widespread, inflammation.
JAK inhibitors, such as Xeljanz, block JAK receptors from signaling other immune responses.
Xeljanz treats chronic inflammatory disorders that include RA, psoriatic arthritis, and ulcerative colitis.
How to take and dosage
Xeljanz comes in two varieties, which are a regular tablet or an extended release (XR) tablet. People can take Xeljanz tablets whole, with or without food.
Adults with RA and psoriatic arthritis can choose between the following dosages:
Xeljanz regular: 5 milligrams (mg) twice daily
Xeljanz XR: 11 mg once daily
Adults with ulcerative colitis will take 10 mg of regular Xeljanz twice daily for at least 8 weeks. After this period, their doctor will reevaluate their symptoms.
Depending on how the person responds to the treatment, a doctor may recommend reducing the dosage to 5 mg twice daily.
People can take Xeljanz in combination with disease modifying drugs, such as methotrexate or azathioprine. However, they will take half the regular dose of Xeljanz.
People who have kidney or liver damage may have more difficulty metabolizing Xeljanz. This means that they will have higher concentrations of the medication in their blood. Doctors will prescribe lower doses for people who have moderate to severe kidney or liver damage because of this fact.
Doctors may interrupt the treatment if a person develops the following conditions:
low red blood cell counts, known as anemia
low white blood cell counts, known as neutropenia
low lymphocyte counts, known as lymphopenia
In pregnancy, some evidence suggests a link between Xeljanz and miscarriage, preterm labor, and low birth weight. However, there is currently not enough data to establish a clear link between Xeljanz and adverse birth effects.
The National Institutes of Health (NIH) have an ongoing pregnancy exposure registry to monitor pregnancy outcomes in women who are taking Xeljanz or Xeljanz XR. Women taking Xeljanz can enroll in the pregnancy registry by calling the toll-free number 1-977-311-8972.
What is rheumatoid arthritis?
This article provides an overview of rheumatoid arthritis, including its causes, symptoms, and treatments.
Side effects of Xeljanz may include headaches, swollen lymph nodes, and excessive sweating.
Xeljanz can cause a variety of side effects, such as:
upper respiratory tract infections
swollen lymph nodes
high blood pressure
shortness of breath
chest or back pain
coughing up blood
clammy or blue-colored skin
Although Xeljanz can help treat immune system-related inflammatory disorders, it can cause adverse effects in specific populations, as follows:
Xeljanz affects the immune system, which can leave people vulnerable to infections.
According to the NIH, serious infections among adults taking Xeljanz usually affect people over 65 years of age, and those who have diabetes.
People who have low lymphocyte counts should not take Xeljanz. An individual who experiences frequent severe infections can take Xeljanz, but they should carefully consider the costs and benefits of this treatment option with their doctor.
People who have RA may have a higher risk of developing some cancers, such as lung, skin, and lymphoma.
A common problem that doctors associate with immunosuppressive treatments, such as tofacitinib, in people with RA is an increased risk of nonmelanoma skin cancer.
In 2019, the FDA released a safety announcement citing a clinical trial that found an increased rate of blood clots in the lungs, or pulmonary embolism, of people with RA who were taking 10 mg of Xeljanz and Xeljanz XR twice daily.
The FDA has approved 10 mg twice daily to treat ulcerative colitis, but not RA or psoriatic arthritis.
Xeljanz may interact with specific medications, including:
moderate to strong CP3A4 inhibitors, such as ketoconazole
strong CP3A4 inducers, such as rifampin
strong CYP2C19 inhibitors, such as fluconazole
immunosuppressive drugs, such as azathioprine, cyclosporine, and tacrolimus
People must inform their doctors of any current medications they are taking before starting Xeljanz.
Private insurance companies usually cover the cost of Xeljanz.
Xeljanz has no generic alternatives at this time. The cost of Xeljanz varies, depending on an individual’s insurance. Private insurance companies can cover most of the cost, if not the entire cost.
Medicare Part D and Medicaid can cover a portion of the cost. People eligible for the Pfizer Patient Assistance Program can receive Xeljanz or Xeljanz XR at no cost.
People who do not have insurance can get more information and apply for financial assistance at the Xeljanz website here.
Xeljanz is a prescription medication that doctors give to treat inflammatory conditions, such as RA, psoriatic arthritis, and ulcerative colitis.
Xeljanz acts as a JAK inhibitor and lowers the body’s immune response. This action can help control inflammation, but it can also leave the body vulnerable to severe infections.